HomeCompareAGFAF vs MRK

AGFAF vs MRK: Dividend Comparison 2026

AGFAF yields 13333.33% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGFAF wins by $944051876715324800.00M in total portfolio value
10 years
AGFAF
AGFAF
● Live price
13333.33%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$944051876715324800.00M
Annual income
$930,326,183,604,330,300,000,000.00
Full AGFAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — AGFAF vs MRK

📍 AGFAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGFAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGFAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGFAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGFAF
Annual income on $10K today (after 15% tax)
$1,133,333.33/yr
After 10yr DRIP, annual income (after tax)
$790,777,256,063,680,700,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, AGFAF beats the other by $790,777,256,063,680,700,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGFAF + MRK for your $10,000?

AGFAF: 50%MRK: 50%
100% MRK50/50100% AGFAF
Portfolio after 10yr
$472025938357662400.00M
Annual income
$465,163,091,802,165,140,000,000.00/yr
Blended yield
98.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AGFAF
No analyst data
Altman Z
-1548.6
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGFAF buys
0
MRK buys
0
No recent congressional trades found for AGFAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGFAFMRK
Forward yield13333.33%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$944051876715324800.00M$56.8K
Annual income after 10y$930,326,183,604,330,300,000,000.00$9,798.13
Total dividends collected$943142383073684224.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AGFAF vs MRK ($10,000, DRIP)

YearAGFAF PortfolioAGFAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,344,033$1,333,333.33$11,206$366.19+$1.33MAGFAF
2$168,918,905$167,480,789.20$12,650$502.35+$168.91MAGFAF
3$19,852,785,021$19,672,041,793.12$14,407$694.19+$19852.77MAGFAF
4$2,182,013,981,744$2,160,771,501,770.83$16,585$967.82+$2182013.97MAGFAF
5$224,287,824,199,531$221,953,069,239,064.90$19,342$1,363.89+$224287824.18MAGFAF
6$21,561,870,489,323,890$21,321,882,517,430,390.00$22,913$1,947.19+$21561870489.30MAGFAF
7$1,938,749,165,623,537,400$1,915,677,964,199,961,300.00$27,662$2,823.89+$1938749165623.51MAGFAF
8$163,055,200,603,353,700,000$160,980,738,996,136,500,000.00$34,159$4,173.35+$163055200603353.69MAGFAF
9$12,827,750,571,022,997,000,000$12,653,281,506,377,408,000,000.00$43,337$6,308.80+$12827750571022998.00MAGFAF
10$944,051,876,715,324,800,000,000$930,326,183,604,330,300,000,000.00$56,776$9,798.13+$944051876715324800.00MAGFAF

AGFAF vs MRK: Complete Analysis 2026

AGFAFStock

Digicann Ventures Inc., together with its subsidiaries, operates in the cannabis industry. The company was formerly known as Agra Ventures Ltd. and changed its name to Digicann Ventures Inc. in August 2023. Digicann Ventures Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada.

Full AGFAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AGFAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGFAF vs SCHDAGFAF vs JEPIAGFAF vs OAGFAF vs KOAGFAF vs MAINAGFAF vs JNJAGFAF vs ABBVAGFAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.